U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07386717) titled 'Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis' on Jan. 27.
Brief Summary: Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life. Although targeted therapies such as Janus kinase inhibitors and interleukin-17 inhibitors have demonstrated efficacy in randomized controlled trials, real-world comparative evidence between these treatment strategies remains limited.
This observational cohort study aims to compare the real-world effectiveness and safety of upadacitini...